The first approved drug to slow the progression of the illness will come with a strong safety warning about potentially life-threatening side effects.

  • agentshags
    link
    fedilink
    arrow-up
    2
    ·
    1 year ago

    Leqembi, from Japanese drugmaker Eisai and U.S.-based drugmaker Biogen, targets a type of protein in the brain called beta-amyloid, long thought by scientists to be one of the underlying causes of Alzheimer’s disease.